Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Effekter av diettfosfor på fosfor og kalsium i hele kroppsbalansen og kinetikk ved moderat CKD

2. november 2026 oppdatert av: University of Minnesota

The aim of the study is to look at the effects of dietary phosphorus on phosphorous and calcium whole-body balance and kinetics in moderate chronic kidney disease (CKD). N = 14 enrolled subjects will be randomly assigned to a cross-over order of (A) Low P Diet, High P Diet. Each cross-over phase will be 19 days and consist of a 7-day outpatient, controlled diet period, followed by a 5- day inpatient, controlled diet, balance, and kinetic study period, followed by a second 7-day outpatient, controlled diet period.

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Detaljert beskrivelse

Chronic kidney disease (CKD) affects approximately 37 million (1 in 7) U.S. adults, most of whom experience mineral and bone disorders (CKD-MBD) that increase risk for cardiovascular events, bone fractures, and death. Dietary and pharmaceutical treatments for CKD-MBD have diverse effects on serum calcium and phosphorus levels, but their effects on the underlying physiological processes of calcium and phosphorus balance are largely unknown. This study aims to determine the effects of a low versus high phosphorus bioaccessibility diet on whole-body calcium and phosphorus balance and kinetics, including measures such as estimated intestinal absorption. This study will be a randomized two-phase cross-over design trial that will include a controlled study diet, a phosphorus isotope as a tracer for kinetic modeling, stool and urine collections, and blood draws. After screening, eligible participants who choose to enroll in the study will be asked to participate in two cross-over sessions, each of approximately 3 weeks (19 days) duration during which time all food will be provided according to the randomized diet intervention assignment. After the first week on the study diet, participants will be asked to stay at the clinical research center when they will be given oral and intravenous doses of phosphorus isotope. Serial blood draws and complete urine and fecal collections will be made for 5 days, then the final week will only include blood draws. Between cross-over sessions, there will be a washout period of 1-3 weeks. Participants will then switch diets and repeat the same study process as the first session. Calcium and phosphorus whole-body balance, intestinal absorption, renal excretion, and movement to and from bone will be determined for both minerals. This project will provide foundational knowledge of calcium and phosphorus physiology in CKD that will support progress towards preventing morbidity and mortality associated with CKD-MBD.

Studietype

Intervensjonell

Registrering (Antatt)

14

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Kathleen Hill Gallant, PhD
  • Telefonnummer: 612-625-5285
  • E-post: hillkm@umn.edu

Studer Kontakt Backup

Studiesteder

    • Indiana
      • Indianapolis, Indiana, Forente stater, 46202
        • Indiana University School of Medicine
        • Ta kontakt med:
          • Mary Balmes-Fenwick
          • Telefonnummer: 317-948-7772
          • E-post: mbalmes@iu.edu
        • Hovedetterforsker:
          • Sharon M Moe, MD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

30 år til 75 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Men or women, ages 30-75 years old, any race or ethnicity
  • Moderate CKD, defined by KDIGO as eGFR category 3b (30-44 mL/min) or 4 (16-29 mL/min) with albuminuria categories A1-A3
  • Serum intact parathyroid hormone above assay normal limit
  • Female subjects must be postmenopausal (>12 months since last menstrual period), surgically sterile, or confirmed not pregnant by pregnancy test
  • Must be on stable doses of medications (except those noted in exclusion criteria) for at least 4 weeks prior to the study
  • Willing to discontinue supplements (e.g., vitamin D, calcium, multivitamin/minerals, or others) upon enrollment until completion of the study
  • Adequate vitamin D status defined as serum 25D > 20 ng/mL based on National Academy of Medicine (then Institute of Medicine) criteria.

Exclusion Criteria:

  • Plans to initiate dialysis within 6 months
  • Hypercalcemia defined as corrected serum calcium >9.8 mg/dL within past 3 months
  • Hyperkalemia defined as serum potassium >5.5 mg/dL within past 3 months
  • Hyperphosphatemia defined as serum phosphate >5.5 mg/dL within past 3 months
  • Intestinal disease that alters absorption or normal intestinal function including celiac disease, small bowel resection, bariatric surgery, or chronic diarrhea/malabsorption
  • Serious, uncontrolled underlying systemic disease including diabetes, lupus, hypertension in the opinion of their physician
  • Pregnant or breastfeeding
  • Prescribed and taken a phosphate binder medication, calcitriol, vitamin D analogs, calcimimetics, PTH analogues, and other medications that may alter Ca and P metabolism within past 4 weeks
  • Non-English speaking

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Grunnvitenskap
  • Tildeling: Randomisert
  • Intervensjonsmodell: Crossover-oppdrag
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: CKD patients group 1

assigned to Low P Diet (LP) then High P Diet (HP),

Cross-over order of LP then HP diet. Each cross-over phase will be 19 days and consist of a 7-day outpatient, controlled diet period, followed by a 5-day inpatient, controlled diet, balance, and kinetic study period, followed by a second 7-day outpatient, controlled diet period.

Eksperimentell: CKD patients group 2

assigned to HP, then LP.

Cross-over order of HP then LP diet. Each cross-over phase will be 19 days and consist of a 7-day outpatient, controlled diet period, followed by a 5-day inpatient, controlled diet, balance, and kinetic study period, followed by a second 7-day outpatient, controlled diet period.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Phosphorus Balance
Tidsramme: 5 days

Determined by analysis of phosphorus content in complete 24-hour urine and stool collections, subtracted from the diet phosphorus content consumed

5 days
Calcium Balance
Tidsramme: 5 days

Determined by analysis of calcium content in complete 24-hour urine and stool collections, subtracted from the diet calcium content consumed

5 days

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Fractional phosphorus absorption
Tidsramme: 12 days

Determined by kinetic modeling of serum, urine, and stool P-33 isotope after oral and IV isotope administrations

12 days
Bone phosphorus balance
Tidsramme: 12 days

Determined by kinetic modeling of serum, urine, and stool P-33 isotope after oral and IV isotope administrations

12 days
Bone calcium balance
Tidsramme: 5 days and 12 days

Determined from the natural stable isotope ratio of 44-Ca to 42-Ca in serum and urine

5 days and 12 days
Urine phosphorus
Tidsramme: 1 week

Determined from the 24-hour urine collections over 1 week (daily average)

1 week
Urine calcium
Tidsramme: 1 week

Determined from the 24-hour urine collections over 1 week (daily average)

1 week
Net phosphorus absorption
Tidsramme: 1 week

Determined by analysis of phosphorus content in complete stool collections, subtracted from the diet phosphorus content consumed, divided by the diet phosphorus consumed.

1 week
Net calcium absorption
Tidsramme: 1 week

Determined by analysis of calcium content in complete stool collections, subtracted from the diet calcium content consumed, divided by the diet phosphorus consumed

1 week
Creatinine clearance
Tidsramme: 2hours, day 8

Creatinine clearance will be determined from the 2-hour fasting urine and a mid-point blood sample collected on Day 8.

2hours, day 8
Serum Fibroblast growth factor-23
Tidsramme: Day1, Day8

Measured in a fasting blood collection on Day 1 and Day 8.

Day1, Day8
Serum Parathyroid hormone
Tidsramme: Day1, Day8

Measured in a fasting blood collection on Day 1 and Day 8.

Day1, Day8
Serum 1,25-dihydroxyvitamin D
Tidsramme: Day1, Day8

Measured in a fasting blood collection on Day 1 and Day 8.

Day1, Day8
Serum phosphate
Tidsramme: Day1, Day8

Measured in a fasting blood collection on Day 1 and Day 8.

Day1, Day8
Serum calcium
Tidsramme: Day1, Day8

Measured in a fasting blood collection on Day 1 and Day 8.

Day1, Day8

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Etterforskere

  • Hovedetterforsker: Kathleen Hill Gallant, PhD, University of Minnesota

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. desember 2026

Primær fullføring (Antatt)

1. mai 2027

Studiet fullført (Antatt)

1. mai 2027

Datoer for studieregistrering

Først innsendt

26. november 2024

Først innsendt som oppfylte QC-kriteriene

26. november 2024

Først lagt ut (Faktiske)

2. desember 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

3. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • TBD2

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere